Coronado Industries Receives European 2A CE Certification for Its Glaucoma Treatment Device; An Essential Part of the Company's Growth Plan is Firmly in Place.

FOUNTAIN HILLS, Ariz. -- Coronado Industries Inc. (OTCBB: CDIK), the manufacturer of unique proprietary pneumatic devices for the treatment of glaucoma, announced today that the company has been notified that their application for 2A CE certification covering its glaucoma treatment device has been approved.

The 2A certification covers both the automated vacuum controller and disposable ring used to administer Coronado's patented PNT process. Successful completion of the 2A certification process allows for the company to now promote and market its products freely throughout the European Union.

Richard Smith, chairman and CEO of the company, stated, "The successful completion of the 2A CE certification process marks a significant new milestone for the company. It was a major objective and an essential component of our business strategy. Our entire management team, lead by Dr. Francesco Aspes and Dr. John Sharkey, has worked tirelessly to address all the items required by the Notified Body to approve our application. Receipt of the 2A certification will allow us to freely distribute our product throughout the European Union and propels us forward in fully developing the potential of our innovative technology." The company also stated that receipt of the 2A certification should allow them to accelerate their efforts to obtain permission to market their products in additional countries outside of the EU.

Francesco Aspes, M.D., Coronado's director of European operations, commented that with the successful completion of the 2A certification process he now looked forward to continue working closely with Coronado's distribution partners in Italy, Spain and Portugal. "Plans are already in place to initiate equipment placement and to promote general adoption of PNT as a potent tool in the treatment arsenal of the glaucoma specialist. As we successfully launch the PNT device with our distribution partners Eupharmed s.r.l. and Izasa S.A., the benefits of incorporating PNT into the overall treatment regime of glaucoma patients will become readily apparent," he said. Aspes also added that he anticipates the company will be able to conclude additional distribution agreements with partners in several other EU countries over the next few months.

John W. Sharkey, Ph.D., Coronado's director of operations, stated that the approval of the 2A application was the final component necessary in their strategy to launch the PNT device in the European Union. "Following receipt of our ISO 13488 certification we began to prepare our launch supplies in anticipation of the 2A approval. We also have sufficient capacity in place to meet the anticipated demand of our current and future distribution partners," he said. "We are ready to immediately initiate delivery of product to our distribution partners," and, "With manufacturing in place and Dr. Aspes focusing on European expansion we can now move forward with implementing our strategy toward obtaining registrations within other major markets such as the United States."

Coronado Industries has, for seven years, been dedicated to its patented glaucoma treatment device. Through its wholly owned subsidiary, Ophthalmic International, it focuses on the development of its patented procedure as a cost-effective alternative for the treatment of the most common types of glaucoma which are open angle and pigmentary.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the company's products, increased levels of competition for the company, new products and technological changes, the company's dependence on third-party suppliers, and other risks detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission.